Acme United (ACU) Q2 Earnings Beat Estimates on MyMedic Acquisition and Margin Expansion

• Acme United reported Q2 FY2026 net sales of $62.7 million, a 16% year-over-year increase that surpassed the $58.1 million consensus estimate.
• Earnings per share reached $1.22, significantly outperforming the $0.81 forecast and driving a nearly 12% surge in stock price.
• Gross margins expanded to 42.6% from 41.0% in the prior year period, reflecting improved pricing power and product mix.
• The company anticipates continued margin recovery as lower-cost inventory replaces higher-tariff stock through the remainder of the year.

Acme United Corporation delivered robust second-quarter FY2026 results, underscoring strong operational momentum and successful strategic integration. Net sales climbed 16% year-over-year to $62.7 million, easily clearing the $58.1 million consensus estimate. This performance was largely fueled by the acquisition of MyMedic, which contributed 16% to top-line growth, alongside an 8% increase in organic core business lines.

Earnings per share (EPS) came in at $1.22, beating analyst expectations of $0.81 by a wide margin. The positive surprise triggered a 17.52% jump in the stock price, pushing shares near their 52-week high of $51.88. The market reaction highlighted investor confidence in navigating inflationary pressures and tariff-related headwinds while executing on its growth strategy.

Gross margins expanded to 42.6% from 41.0% in the same period last year, signaling effective cost management and strategic pricing initiatives. Management attributes this improvement to a favorable product mix and enhanced operational efficiency across key segments. Chief Executive Officer Walter Johnsen emphasized that the company maintains strong pricing power, allowing it to absorb certain cost increases without eroding profitability.

How Is the MyMedic Acquisition Driving Growth?

The acquisition of MyMedic has emerged as a central pillar of Acme United’s growth strategy, expanding its tactical and emergency response product markets footprint. Beyond direct-to-consumer channels, the company is actively pursuing integration into mass retail distribution networks. This expansion is expected to unlock recurring revenue streams and enhance brand visibility in high-growth safety segments.

Management views the integration of MyMedic as a key catalyst for long-term value creation, particularly in the first aid and safety category. Strategic investments in automation and new product lines are supporting these efforts, aiming to improve operational efficiency and scalability. The company has set an ambitious target of reaching $300 million in revenue within three years, driven by these expansion initiatives.

What Are the Key Risks and Margin Recovery Outlook?

Despite the strong quarterly performance, Acme United faces several headwinds that investors should monitor closely. Selling, General, and Administrative (SG&A) expenses remain elevated at 32% of sales, reflecting the costs of integrating new assets and expanding distribution. However, management expects SG&A efficiency to improve as the integration of MyMedic matures and operational synergies are realized.

Tariff-related inventory costs continue to pose a challenge, though management anticipates easing pressures as lower-cost stock replaces higher-tariff inventory by year-end. Currency volatility and uneven geographic performance, particularly in the Canadian market, also present risks to future earnings. Freight cost fluctuations and broader inflationary trends may further impact cost structures in the near term.

Looking ahead, Acme United expects strong profitability in Q4 driven by seasonal demand in its safety and cutting instrument segments. The next earnings release is scheduled for October 20, 2026, with consensus estimates projecting an EPS of $0.67. Investors will be watching for sustained margin expansion and successful execution of the MyMedic integration strategy as key indicators of long-term success.